Roche Holding AG’s shares just posted their best month since 1997, lifted by optimism over an experimental breast cancer pill and encouraging trial results. Analysts see further gains ahead.
November’s 19% surge in the Swiss drugmaker’s stock gained traction after Roche said its giredestrant medicine helped women with a form of early breast cancer. That followed news of two late-stage trials showing a multiple sclerosis drug could work for most forms of the disease.